Facebook Instagram X-twitter Linkedin

LL37 (5mg)

Table of Contents

  • Quickstart Highlights

LL-37 (5mg) protocols focus on this synthetic version of the human antimicrobial peptide cathelicidin (LL-37), studied for its potential role in immune modulation, antimicrobial defense, inflammation regulation, and tissue repair. LL-37 is part of the innate immune system and is being researched for its broad activity against bacteria, viruses, and fungi, as well as its role in wound healing. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 100–500 mcg once daily (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support immune function, antimicrobial defense, and tissue repair
  • Schedule: Daily or intermittent subcutaneous injections depending on protocol
  • Dose Range: 100–500 mcg per day
  • Dosing Protocol

Suggested approach for the 5 mg vial format.

  • Start: 100–200 mcg once daily to assess tolerance
  • Target: 250–500 mcg once daily (or every other day in sensitive users)
  • Frequency: Once daily or cyclic use (subcutaneous)
  • Vial Duration: One 5 mg vial lasts approximately 10–50 days, depending on dose
  • Timing: Flexible; often taken at the same time daily for consistency
  • Mechanism of Action

LL-37 is a human antimicrobial peptide belonging to the cathelicidin family. It is naturally produced by immune cells such as neutrophils and epithelial cells as part of the innate immune response.

LL-37 works by disrupting microbial cell membranes, leading to broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. Beyond antimicrobial effects, it also modulates immune responses by influencing cytokine production, reducing excessive inflammation, and supporting tissue repair processes. Research suggests LL-37 may also play a role in wound healing and maintaining barrier integrity in skin and mucosal tissues.

  • Potential Benefits & Side Effects

Observations based on preclinical and early research.

Potential Benefits:

  • May support innate immune defense against pathogens
  • May promote faster wound and tissue healing
  • May help regulate inflammatory responses
  • Broad-spectrum antimicrobial activity in research models

Possible Side Effects:

  • Temporary flu-like symptoms or fatigue in some users
  • Mild injection-site irritation
  • Possible immune activation reactions at higher doses
  • Long-term human safety data are limited; it remains investigational